Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC.RLMD · Entity 5498 | Director · COO | December 12, 2025 | December 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RELMADA THERAPEUTICS, INC.
Report date December 12, 2025 · Filed December 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $4.06 · Expires 2035-12-12 | Direct | 828,000 |
Reported balance
After 2025-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-12 · Grant · Acquired 828,000 · Balance 828,000 F1: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2021 Filed Jan 26, 2021 19:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 300 | $36.18 | $10,854.00 |
DisclosureSEC source: 0001213900-21-004482 · ownership.xml · nonDerivative · entry 3 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,280 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $36.06 to $36.37 per share, inclusive. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 19:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,800 | $3,543.00 | $6,377,400.00 |
DisclosureSEC source: 0001213900-21-004482 · ownership.xml · nonDerivative · entry 2 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,580 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $35.04 to $35.98 per share, inclusive. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 19:30 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 4,085 | $3.24 | $13,235.40 |
DisclosureSEC source: 0001213900-21-004482 · ownership.xml · nonDerivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2021 Filed Jan 27, 2021 06:48 UTC Amendment | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,800 | $35.43 | $63,774.00 |
DisclosureSEC source: 0001213900-21-004512 · ownership.xml · nonDerivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,580 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales price range from $35.04 to $35.98 per share, inclusive. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 16:08 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 150,000 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001213900-21-001421 · ownership.xml · derivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-01-07 F1 · derivative.exercise_date: The options vest from the date of grant in quarterly increments of 6.25%. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 16:16 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 22,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-20-022888 · ownership.xml · derivative · entry 3 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,500 Underlying: Common Stock · 22,000 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 16:16 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Tax withholdingCommon Stock | 1,826 | $39.03 | $71,268.78 |
DisclosureSEC source: 0001213900-20-022888 · ownership.xml · nonDerivative · entry 2 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,295 F1 · shares: Reflects 1,826 shares withheld at the market price of $39.03 per share to fund the cashless exercise of 22,000 options owned by Mr. Kelly, which cashless exercise was approved in advance by the Board of Directors. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 16:16 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 22,000 | $3.24 | $71,280.00 |
DisclosureSEC source: 0001213900-20-022888 · ownership.xml · nonDerivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 16:56 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 150,000 | $43.47 Strike: $43.47 | $6,520,500.00 |
DisclosureSEC source: 0001213900-19-026855 · ownership.xml · derivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. Read SEC document |
| October 18, 2019 Filed Oct 21, 2019 16:07 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 3,100 | $19.20 | $59,520.00 |
DisclosureSEC source: 0001213900-19-020706 · ownership.xml · nonDerivative · entry 7 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,121 Read SEC document |
| October 18, 2019 Filed Oct 21, 2019 16:07 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 100 | $19.15 | $1,915.00 |
DisclosureSEC source: 0001213900-19-020706 · ownership.xml · nonDerivative · entry 6 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,021 Read SEC document |
| October 18, 2019 Filed Oct 21, 2019 16:07 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 200 | $19.10 | $3,820.00 |
DisclosureSEC source: 0001213900-19-020706 · ownership.xml · nonDerivative · entry 5 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,921 Read SEC document |
| October 18, 2019 Filed Oct 21, 2019 16:07 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 100 | $19.08 | $1,908.00 |
DisclosureSEC source: 0001213900-19-020706 · ownership.xml · nonDerivative · entry 4 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,721 Read SEC document |
| October 18, 2019 Filed Oct 21, 2019 16:07 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 400 | $19.07 | $7,628.00 |
DisclosureSEC source: 0001213900-19-020706 · ownership.xml · nonDerivative · entry 3 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,621 Read SEC document |
| October 18, 2019 Filed Oct 21, 2019 16:07 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 100 | $19.04 | $1,904.00 |
DisclosureSEC source: 0001213900-19-020706 · ownership.xml · nonDerivative · entry 2 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,221 Read SEC document |
| October 18, 2019 Filed Oct 21, 2019 16:07 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 1,000 | $18.99 | $18,990.00 |
DisclosureSEC source: 0001213900-19-020706 · ownership.xml · nonDerivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,121 Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 17:07 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 600,000 | $2.20 Strike: $2.20 | $1,320,000.00 |
DisclosureSEC source: 0001213900-19-014041 · ownership.xml · derivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2029-07-29 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. Read SEC document |
| May 14, 2019 Filed May 15, 2019 16:07 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseWarrant · Derivative | 50,000 | $2.25 Strike: $2.25 | $112,500.00 |
DisclosureSEC source: 0001213900-19-008815 · ownership.xml · derivative · entry 2 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common stock · 50,000 shares Expires 2024-05-14 Read SEC document |
| May 14, 2019 Filed May 15, 2019 16:07 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 100,000 | $1.50 | $150,000.00 |
DisclosureSEC source: 0001213900-19-008815 · ownership.xml · nonDerivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 488,483 Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 16:54 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 500,000 | $1.15 Strike: $1.15 | $575,000.00 |
DisclosureSEC source: 0001213900-18-017634 · ownership.xml · derivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-12-20 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. Read SEC document |
| December 11, 2018 Filed Dec 11, 2018 16:21 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 5,000 | $1.21 | $6,065.00 |
DisclosureSEC source: 0001213900-18-017210 · ownership.xml · nonDerivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,483 Read SEC document |
| October 18, 2018 Filed Oct 19, 2018 13:02 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | ConversionCommon Stock | 223,483 | $0.72 | $160,907.76 |
DisclosureSEC source: 0001213900-18-014143 · ownership.xml · nonDerivative · entry 2 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2018 Filed Oct 19, 2018 13:02 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseWarrant · Derivative | 97,500 | $1.50 Strike: $1.50 | $146,250.00 |
DisclosureSEC source: 0001213900-18-014143 · ownership.xml · derivative · entry 3 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,500 Underlying: Common stock · 97,500 shares Expires 2023-10-12 Read SEC document |
| October 12, 2018 Filed Oct 19, 2018 13:02 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 150,000 | $0.90 | $135,000.00 |
DisclosureSEC source: 0001213900-18-014143 · ownership.xml · nonDerivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Read SEC document |
| October 20, 2017 Filed Oct 23, 2017 16:38 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 450,000 | $0.81 Strike: $0.81 | $364,500.00 |
DisclosureSEC source: 0001213900-17-010833 · f4101917kelly_relmada.xml · derivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2027-10-20 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 11:10 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseWarrant · Derivative | 100,000 | $1.50 Strike: $1.50 | $150,000.00 |
DisclosureSEC source: 0001213900-17-010350 · f4100417kelly_relmadatherap.xml · derivative · entry 2 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common stock · 100,000 shares Expires 2024-10-04 Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 11:10 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseConvertible Note · Derivative | 200,000 | $0.75 Strike: $0.75 | $150,000.00 |
DisclosureSEC source: 0001213900-17-010350 · f4100417kelly_relmadatherap.xml · derivative · entry 1 Kelly Paul Edward · CIK 0001658544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common stock · 200,000 shares Expires 2019-10-04 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.